Search results
Results from the WOW.Com Content Network
Financials as of September 30, 2023. [update] [1] Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale company and a contract research organization that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. [2]
1961 or 1962 (age 62–63) [1] South Africa. Title. Chairman, president and CEO, AmerisourceBergen. Predecessor. R. David Yost. Successor. incumbent. Steven H. Collis (born 1961) is an American businessman, the chairman, president and chief executive officer (CEO) of Cencora, previously known as AmerisourceBergen.
AmerisourceBergen (ABC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe. Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to be driven by its core Pharmaceutical Distribution business despite a competitive industry.
AmerisourceBergen (ABC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AmerisourceBergen's (ABC) fiscal third-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q4. AmerisourceBergen (ABC) Beats on Q4 Earnings, Issues '19 View Skip ...